BIOMARIN PHARMACEUTICAL INC — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that BIOMARIN PHARMACEUTICAL INC filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 31, 2017 | $1.31B | Feb 26, 2018 |
| FY2017 | Dec 31, 2016 | $1.12B | Feb 26, 2018 |
| FY2017 | Dec 31, 2015 | $889.90M | Feb 26, 2018 |
| FY2016 | Dec 31, 2014 | $749.28M | Feb 27, 2017 |
| FY2015 | Dec 31, 2013 | $548.49M | Feb 29, 2016 |
| FY2014 | Dec 31, 2012 | $500.72M | Mar 2, 2015 |
| FY2013 | Dec 31, 2011 | $441.36M | Feb 26, 2014 |
| FY2012 | Dec 31, 2010 | $376.27M | Feb 26, 2013 |
| FY2011 | Dec 31, 2009 | $324.66M | Feb 22, 2012 |
| FY2010 | Dec 31, 2008 | $296.49M | Feb 24, 2011 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.22B | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $2.85B | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $2.42B | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | $2.10B | Feb 24, 2025 |
| FY2023 | Dec 31, 2021 | $1.85B | Feb 26, 2024 |
| FY2022 | Dec 31, 2020 | $1.86B | Feb 27, 2023 |
| FY2021 | Dec 31, 2019 | $1.70B | Feb 25, 2022 |
| FY2020 | Dec 31, 2018 | $1.49B | Feb 26, 2021 |
| FY2019 | Dec 31, 2017 | $1.31B | Feb 27, 2020 |
| FY2018 | Dec 31, 2016 | $1.12B | Feb 28, 2019 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $348.90M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $426.86M | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $167.65M | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | $141.56M | Feb 24, 2025 |
| FY2023 | Dec 31, 2021 | ($64.08M) | Feb 26, 2024 |
| FY2022 | Dec 31, 2020 | $854.03M | Feb 27, 2023 |
| FY2021 | Dec 31, 2019 | ($23.85M) | Feb 25, 2022 |
| FY2020 | Dec 31, 2018 | ($77.21M) | Feb 26, 2021 |
| FY2019 | Dec 31, 2017 | ($117.04M) | Feb 27, 2020 |
| FY2018 | Dec 31, 2016 | ($630.21M) | Feb 28, 2019 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $409.48M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $484.21M | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $185.77M | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | $160.97M | Feb 24, 2025 |
| FY2023 | Dec 31, 2021 | ($82.34M) | Feb 26, 2024 |
| FY2022 | Dec 31, 2020 | ($43.44M) | Feb 27, 2023 |
| FY2021 | Dec 31, 2019 | ($100.46M) | Feb 25, 2022 |
| FY2020 | Dec 31, 2018 | ($123.52M) | Feb 26, 2021 |
| FY2019 | Dec 31, 2017 | ($14.70M) | Feb 27, 2020 |
| FY2018 | Dec 31, 2016 | ($803.43M) | Feb 28, 2019 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $921.93M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $747.18M | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $746.77M | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | $649.61M | Feb 24, 2025 |
| FY2023 | Dec 31, 2021 | $628.79M | Feb 26, 2024 |
| FY2022 | Dec 31, 2020 | $628.12M | Feb 27, 2023 |
| FY2021 | Dec 31, 2019 | $715.01M | Feb 25, 2022 |
| FY2020 | Dec 31, 2018 | $696.33M | Feb 26, 2021 |
| FY2019 | Dec 31, 2017 | $610.75M | Feb 27, 2020 |
| FY2018 | Dec 31, 2016 | $661.91M | Feb 28, 2019 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.15B | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $1.01B | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $892.41M | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | $823.24M | Feb 24, 2025 |
| FY2023 | Dec 31, 2021 | $759.38M | Feb 26, 2024 |
| FY2022 | Dec 31, 2020 | $737.67M | Feb 27, 2023 |
| FY2021 | Dec 31, 2019 | $680.92M | Feb 25, 2022 |
| FY2020 | Dec 31, 2018 | $604.35M | Feb 26, 2021 |
| FY2019 | Dec 31, 2017 | $554.34M | Feb 27, 2020 |
| FY2018 | Dec 31, 2016 | $476.59M | Feb 28, 2019 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $827.99M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $572.84M | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $159.26M | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | $175.90M | Feb 24, 2025 |
| FY2023 | Dec 31, 2021 | $304.54M | Feb 26, 2024 |
| FY2022 | Dec 31, 2020 | $85.37M | Feb 27, 2023 |
| FY2021 | Dec 31, 2019 | $48.26M | Feb 25, 2022 |
| FY2020 | Dec 31, 2018 | $20.21M | Feb 26, 2021 |
| FY2019 | Dec 31, 2017 | ($8.76M) | Feb 27, 2020 |
| FY2018 | Dec 31, 2016 | ($227.84M) | Feb 28, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $103.04M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $85.42M | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $96.69M | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | $120.96M | Feb 24, 2025 |
| FY2023 | Dec 31, 2021 | $95.58M | Feb 26, 2024 |
| FY2022 | Dec 31, 2020 | $114.31M | Feb 27, 2023 |
| FY2021 | Dec 31, 2019 | $145.03M | Feb 25, 2022 |
| FY2020 | Dec 31, 2018 | $144.62M | Feb 26, 2021 |
| FY2019 | Dec 31, 2017 | $199.22M | Feb 27, 2020 |
| FY2018 | Dec 31, 2016 | $148.38M | Feb 28, 2019 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $7.59B | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $6.99B | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | $6.84B | Feb 24, 2025 |
| FY2023 | Dec 31, 2022 | $6.38B | Feb 26, 2024 |
| FY2022 | Dec 31, 2021 | $6.00B | Feb 27, 2023 |
| FY2021 | Dec 31, 2020 | $5.85B | Feb 25, 2022 |
| FY2020 | Dec 31, 2019 | $4.69B | Feb 26, 2021 |
| FY2019 | Dec 31, 2018 | $4.43B | Feb 27, 2020 |
| FY2018 | Dec 31, 2017 | $4.63B | Feb 28, 2019 |
| FY2017 | Dec 31, 2016 | $4.02B | Feb 26, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.51B | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $1.33B | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | $1.89B | Feb 24, 2025 |
| FY2023 | Dec 31, 2022 | $1.77B | Feb 26, 2024 |
| FY2022 | Dec 31, 2021 | $1.74B | Feb 27, 2023 |
| FY2021 | Dec 31, 2020 | $1.74B | Feb 25, 2022 |
| FY2020 | Dec 31, 2019 | $1.57B | Feb 26, 2021 |
| FY2019 | Dec 31, 2018 | $1.46B | Feb 27, 2020 |
| FY2018 | Dec 31, 2017 | $1.82B | Feb 28, 2019 |
| FY2017 | Dec 31, 2016 | $1.26B | Feb 26, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $6.09B | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $5.66B | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $4.95B | Feb 26, 2026 |
| FY2025 | Dec 31, 2022 | $4.60B | Feb 26, 2026 |
| FY2024 | Dec 31, 2021 | $4.27B | Feb 24, 2025 |
| FY2023 | Dec 31, 2020 | $4.10B | Feb 26, 2024 |
| FY2022 | Dec 31, 2019 | $3.12B | Feb 27, 2023 |
| FY2021 | Dec 31, 2018 | $2.97B | Feb 25, 2022 |
| FY2020 | Dec 31, 2017 | $2.81B | Feb 26, 2021 |
| FY2019 | Dec 31, 2016 | $2.77B | Feb 27, 2020 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $196.20M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $196.20M | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | $196.20M | Feb 24, 2025 |
| FY2023 | Dec 31, 2022 | $196.20M | Feb 26, 2024 |
| FY2022 | Dec 31, 2021 | $196.20M | Feb 27, 2023 |
| FY2021 | Dec 31, 2020 | $196.20M | Feb 25, 2022 |
| FY2021 | Dec 31, 2019 | $197.04M | Feb 25, 2022 |
| FY2020 | Dec 31, 2018 | $197.04M | Feb 26, 2021 |
| FY2018 | Dec 31, 2017 | $197.04M | Feb 28, 2019 |
| FY2017 | Dec 31, 2016 | $197.04M | Feb 26, 2018 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $154.21M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | ($194.70M) | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | ($621.55M) | Feb 24, 2025 |
| FY2023 | Dec 31, 2022 | ($789.20M) | Feb 26, 2024 |
| FY2022 | Dec 31, 2021 | ($930.76M) | Feb 27, 2023 |
| FY2021 | Dec 31, 2020 | ($861.61M) | Feb 25, 2022 |
| FY2020 | Dec 31, 2019 | ($1.72B) | Feb 26, 2021 |
| FY2019 | Dec 31, 2018 | ($1.69B) | Feb 27, 2020 |
| FY2018 | Dec 31, 2017 | ($1.64B) | Feb 28, 2019 |
| FY2017 | Dec 31, 2016 | ($1.52B) | Feb 26, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.31B | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $942.84M | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | $755.13M | Feb 24, 2025 |
| FY2023 | Dec 31, 2022 | $724.53M | Feb 26, 2024 |
| FY2022 | Dec 31, 2021 | $587.28M | Feb 27, 2023 |
| FY2021 | Dec 31, 2020 | $649.16M | Feb 25, 2022 |
| FY2020 | Dec 31, 2019 | $437.45M | Feb 26, 2021 |
| FY2019 | Dec 31, 2018 | $493.98M | Feb 27, 2020 |
| FY2018 | Dec 31, 2017 | $598.03M | Feb 28, 2019 |
| FY2018 | Dec 31, 2016 | $408.33M | Feb 28, 2019 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 1 | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | 2 | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | 0 | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | 0 | Feb 24, 2025 |
| FY2023 | Dec 31, 2021 | 0 | Feb 26, 2024 |
| FY2022 | Dec 31, 2020 | 4 | Feb 27, 2023 |
| FY2021 | Dec 31, 2019 | 0 | Feb 25, 2022 |
| FY2020 | Dec 31, 2018 | 0 | Feb 26, 2021 |
| FY2019 | Dec 31, 2017 | 0 | Feb 27, 2020 |
| FY2018 | Dec 31, 2016 | (3) | Feb 28, 2019 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 1 | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | 2 | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | 0 | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | 0 | Feb 24, 2025 |
| FY2023 | Dec 31, 2021 | 0 | Feb 26, 2024 |
| FY2022 | Dec 31, 2020 | 4 | Feb 27, 2023 |
| FY2021 | Dec 31, 2019 | 0 | Feb 25, 2022 |
| FY2020 | Dec 31, 2018 | 0 | Feb 26, 2021 |
| FY2019 | Dec 31, 2017 | 0 | Feb 27, 2020 |
| FY2018 | Dec 31, 2016 | (3) | Feb 28, 2019 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 192.30M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | 190.76M | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | 188.60M | Feb 24, 2025 |
| FY2023 | Dec 31, 2022 | 186.25M | Feb 26, 2024 |
| FY2022 | Dec 31, 2021 | 183.91M | Feb 27, 2023 |
| FY2021 | Dec 31, 2020 | 181.74M | Feb 25, 2022 |
| FY2020 | Dec 31, 2019 | 179.84M | Feb 26, 2021 |
| FY2019 | Dec 31, 2018 | 178.25M | Feb 27, 2020 |
| FY2018 | Dec 31, 2017 | 175.84M | Feb 28, 2019 |
| FY2017 | Dec 31, 2016 | 172.65M | Feb 26, 2018 |